Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
Infectious Diseases and Therapy
|
April 3, 2024
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Stefan Schneider, Gary Blick, Christina Burke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 27, 2019
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection
Edwin DeJesus, Sara Harward, Roxanne C Jewell, et al.
The Journal of Clinical Investigation
|
June 29, 2023
Active transcription in the vascular bed characterizes rapid progression in idiopathic pulmonary fibrosis
Nirmal S Sharma, Kapil Patel, Ezgi Sari, et al.
Journal of the International AIDS Society
|
September 13, 2022
Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study
Cindy P Garris, Maggie Czarnogorski, Marybeth Dalessandro, et al.
Journal of the International AIDS Society
|
September 12, 2022
Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE)
Maggie Czarnogorski, Cindy P Garris, Marybeth Dalessandro, et al.
The Lancet. HIV
|
December 24, 2022
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
Samir K Gupta, Mezgebe Berhe, Gordon Crofoot, et al.
AIDS (London, England)
|
October 7, 2025
Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naïve people with HIV: randomized study
Debbie Hagins, Mezgebe Berhe, Gordon E Crofoot, et al.
American Journal of Respiratory Cell and Molecular Biology
|
February 13, 2023
Cutaneous Exposure to Arsenicals Is Associated with Development of Constrictive Bronchiolitis in Mice
Ranu Surolia, Fu Jun Li, Kevin Dsouza, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 3, 2015
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
Anton Pozniak, Jose R Arribas, Joseph Gathe, et al.
The Journal of Infectious Diseases
|
September 2, 2025
VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Anti-drug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results
Peter Leone, Alejandro Ferro, Charlotte-Paige Rolle, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
Infectious Diseases and Therapy
|
April 3, 2024
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Stefan Schneider, Gary Blick, Christina Burke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 27, 2019
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection
Edwin DeJesus, Sara Harward, Roxanne C Jewell, et al.
The Journal of Clinical Investigation
|
June 29, 2023
Active transcription in the vascular bed characterizes rapid progression in idiopathic pulmonary fibrosis
Nirmal S Sharma, Kapil Patel, Ezgi Sari, et al.
Journal of the International AIDS Society
|
September 13, 2022
Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study
Cindy P Garris, Maggie Czarnogorski, Marybeth Dalessandro, et al.
Journal of the International AIDS Society
|
September 12, 2022
Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE)
Maggie Czarnogorski, Cindy P Garris, Marybeth Dalessandro, et al.
The Lancet. HIV
|
December 24, 2022
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
Samir K Gupta, Mezgebe Berhe, Gordon Crofoot, et al.
AIDS (London, England)
|
October 7, 2025
Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naïve people with HIV: randomized study
Debbie Hagins, Mezgebe Berhe, Gordon E Crofoot, et al.
American Journal of Respiratory Cell and Molecular Biology
|
February 13, 2023
Cutaneous Exposure to Arsenicals Is Associated with Development of Constrictive Bronchiolitis in Mice
Ranu Surolia, Fu Jun Li, Kevin Dsouza, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 3, 2015
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
Anton Pozniak, Jose R Arribas, Joseph Gathe, et al.
The Journal of Infectious Diseases
|
September 2, 2025
VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Anti-drug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results
Peter Leone, Alejandro Ferro, Charlotte-Paige Rolle, et al.
Page
of 4